Gujarat Pharma sector gearing up to meet the challenges after the implementation of new National Pharma Policy and increased used of generics. This was stated by Dr. Hemant G. Koshia, Commissioner of Food & Drug Control Administration (FDCA), Government of Gujarat. He was speaking at National Food & Pharma Summit 2017 at Ahmedabad organised by elets.
He elaborated that Gujarat is number 1 supplier in terms of WHO-GMP compliant manufacturing facilities. Now emphasis is being put on quality and affordable medicines by Government of India. Due to emphasis being put on use of generics and upcoming National Pharma Policy, scenario is changing at national level. Gujarat Pharma sector gearing up to meet the challenges due to generics. Turnover of Gujarat Pharmaceutical industry was worth USD$ 6.7 Billion in 2015-16; while exports was worth USD% 3.06 Billion. Provides employment to around 85,000 people. More than 255 WHO-GMP compliant manufacturing facilities in India are from Gujarat. Accounts for 53% of the total medical devices manufacturers in the country.
In the inaugural session of the summit Dr. Viranchi Shah, Chairman, Indian Drugs Manufacturer's Association, Gujarat State Board pointed out challenges faces by Pharmacuetical industries and suggested various steps to face the problems. Dr. Pallavi Darade, FDA Commissioner, Maharastra, Geoff Wain, British Deputy HIgh Commissioner, Ahmedabad, Dr. Gaurav Dahiya, Mission Director, National Health Mission, Dr. Jayanti Ravi, Health Commissioner, Gujarat, V R Shah, Deputy Commissioner, FDCA - Gujarat, Dipika Chauhan, Deputy Commissioner, FDCA - Gujarat, T.K. Kannan, CEO, Adani Wilmer, VIshal Rajgarhia, Marketing Director of Finecure Pharmaceuticals also presented their point of views. Dr. Ravi Gupta, CEO elets Technomedia Pvt. Ltd. presented Vote of Thanks.
The global pharmaceutical market size is estimated to reach USD 1.4 trillion and the Indian pharmaceutical market size is estimated as USD 55 billion by the year 2020. The Indian pharmaceutical sector is expected to grow with faster compound annual growth rate (CAGR) compared to global growth rate during the period 2015-2020. The world market will be dominated by countries like USA, EU and Japan and the contribution of Phrmerging countries is expected to be more in coming years. The future of the world pharmaceutical sector will be dominated by medicines for non communicable diseases and original branded medicines. The Indian pharmaceutical sector evolved in different phases from pre independence era to post Trade-Related Aspects of Intellectual Property Rights (TRIPS).
Presently, Indian pharmaceutical sector is dominated by the generics drugs and more drugs are sold in anti-infective category. The Indian pharmaceutical industry is having opportunities in the domestic market with growing demand for quality health care. More opportunities are seen in the area of Contract Research and Manufacturing Services
(CRAMS) by Mergers and Acquisitions (M&A) and Biogenic market. The government of India has taken measures to boost pharmaceutical sector, even though, the pharmaceutical sector is facing challenges in patent rights and methods used for fixing ceiling price for drugs. More challenges are expected due to immature clinical trial regulations and ethical aspects.
The Pharmaceuticals Industry in India is the largest provider of generic drugs globally with the Indian generics accounting for 20% of global exports in terms of volume. India enjoys an important position in the global pharmaceuticals sector. The country also has a large pool of scientists and engineers who have the potential to steer the industry ahead to an even higher level.
Presently, over 80 per cent of the anti-retroviral drugs used globally to combat AIDS (Acquired Immuno Deficiency Syndrome) are supplied by Indian pharmaceutical firms. The UN-backed Medicines Patent Pool has signed six sub-licences with Aurobindo, Cipla, Desano, Emcure, Hetero Labs and Laurus Labs, allowing them to make generic anti-AIDS medicine TenofovirAlafenamide (TAF) for 112 developing countries.
The Union Cabinet has given its nod for the amendment of the existing Foreign Direct Investment (FDI) policy in the pharmaceutical sector in order to allow FDI up to 100 per cent under the automatic route for manufacturing of medical devices subject to certain conditions.
Snaps from the event:
